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Abstract
Background: Genetic variation in IL28B and other factors are associated with sustained virological response (SVR) after
pegylated-interferon/ribavirin treatment for chronic hepatitis C (CHC). Using data from the HALT-C Trial, we developed a
model to predict a patient’s probability of SVR based on IL28B genotype and clinical variables.
Methods: HALT-C enrolled patients with advanced CHC who had failed previous interferon-based treatment. Subjects were
re-treated with pegylated-interferon/ribavirin during trial lead-in. We used step-wise logistic regression to calculate adjusted
odds ratios (aOR) and create the predictive model. Leave-one-out cross-validation was used to predict a priori probabilities
of SVR and determine area under the receiver operator characteristics curve (AUC).
Results: Among 646 HCV genotype 1-infected European American patients, 14.2% achieved SVR. IL28B rs12979860-CC
genotype was the strongest predictor of SVR (aOR, 7.56; p,.0001); the model also included HCV RNA (log10 IU/ml), AST:ALT
ratio, Ishak fibrosis score and prior ribavirin treatment. For this model AUC was 78.5%, compared to 73.0% for a model
restricted to the four clinical predictors and 60.0% for a model restricted to IL28B genotype (p,0.001). Subjects with a
predicted probability of SVR ,10% had an observed SVR rate of 3.8%; subjects with a predicted probability .10% (43.3% of
subjects) had an SVR rate of 27.9% and accounted for 84.8% of subjects actually achieving SVR. To verify that consideration
of both IL28B genotype and clinical variables is required for treatment decisions, we calculated AUC values from published
data for the IDEAL Study.
Conclusion: A clinical prediction model based on IL28B genotype and clinical variables can yield useful individualized
predictions of the probability of treatment success that could increase SVR rates and decrease the frequency of futile
treatment among patients with CHC.
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Introduction
Chronic infection with hepatitis C virus (HCV) is an important
cause of liver cancer and end-stage liver disease in the United
States and worldwide [1,2]. About 60–80% of persons who
become infected with HCV fail to clear the virus spontaneously.
Treatment with pegylated-interferon-alfa/ribavirin is associated
with many adverse effects and results in a sustained virological
response (SVR; i.e., undetectable HCV RNA six months post-
treatment) in only 40–50% of interferon-naı ¨ve patients who are
infected with HCV genotype 1 [3] (the most common viral
genotype in the United States and many other developed
countries) [4]. Recently, genome wide association studies (GWAS)
found single nucleotide polymorphisms (SNPs) located upstream of
IL28B (alternatively known as interferon-l3) to be associated with
SVR [5,6,7,8]. IL28B variants are also associated with decreased
frequency of spontaneous clearance of HCV [6,9]. Interferon-l
induces the JAK/STAT pathway, which up-regulates genes with
anti-viral effects against HCV [10,11]. The newly identified SNPs
likely mark a functional variant that affects response to interferon-
a [12,13].
A goal of genomic research is to yield information that leads to
treatment decisions based on a patient’s genetic makeup [14].
Personalized clinical decision-making for treatment of patients
with chronic hepatitis C requires estimates of the probability that a
patient will achieve SVR which consider not only IL28B genotype,
but also other factors that are associated with treatment response
[12]. Here we examine the association of IL28B genotype with
response to treatment among participants in The Hepatitis C
Antiviral Long-term Treatment against Cirrhosis (HALT-C) Trial,
which enrolled patients with bridging fibrosis or cirrhosis who had
not responded to previous interferon therapy [15]. We use these
results to develop a model that predicts the individual probability
of SVR for such patients based on genotype for the IL28B
rs12979860 SNP and four commonly measured pre-treatment
clinical variables.
Methods
Subjects
The design and primary results of the HALT-C Trial have been
reported [15,16]. Briefly, at enrollment, HALT-C patients had an
Ishak fibrosis score $3 by local assessment of liver biopsy, had not
previously responded to interferon treatment, had a Child-
Turcotte-Pugh score ,7 and had no evidence of hepatocellular
carcinoma. Final assessment of fibrosis stage was performed by a
panel of hepatopathologists [15,16]. Patients with other liver
diseases, human immunodeficiency virus infection, active illicit
drug use or current alcohol abuse were excluded. During lead-in,
patients received pegylated-interferon-a2a 180 mcg/week plus
ribavirin 1.0–1.2 g/day. Subjects with undetectable HCV RNA at
week 20 remained on combination treatment through week 48
and were followed until week 72. Subjects with undetectable HCV
RNA at weeks 48 and 72 were considered to have an SVR.
Investigations of human genetics in the HALT-C Trial were
conducted in those participants who provided (written) consent for
genetic testing. Subjects who reported themselves to be ‘White,’
but not of Latino/Hispanic ethnicity, were termed ‘European
American;’ those who reported themselves to be ‘White’ and of
Latino/Hispanic ethnicity were termed ‘Hispanic;’ those self-
reporting as Black were termed ‘African American.’ Subjects who
did not report themselves to be in one of these three groups
(n=27) were excluded from this analysis. For external comparison,
we genotyped IL28B SNPs in reference populations representative
of European American or African American subjects (Text S1and
Table S1).
The HALT-C Trial was approved by institutional review
boards of the participating institutions: Human Subjects IRB,
University of Massachusetts Medical Center, Worcester, MA;
Human Subjects Protection Office, University of Connecticut
Health Center, Farmington, CT; Biomedical IRB, Saint Louis
University School of Medicine, St Louis, MO; Partners Human
Research Committee, Boston, MA; Colorado Multiple Institu-
tional Review Board, Aurora, CO; University of California -
Irvine Institutional Review Board, Irvine, CA; IRB (Subcommittee
on Human Studies), Long Beach VAMC Research Health Care
Group, Long Beach, CA; Institutional Review Board, University
of Texas Southwestern Medical Center, Dallas, TX; Institutional
Review Board, University of Southern California, Los Angeles,
CA; Institutional Review Board for Human Subject Research,
University of Michigan Medical Center, Ann Arbor, MI; Office of
Research Subjects Protection, Virginia Commonwealth University
Health System, Richmond, VA; Institutional Review Board,
National Institute of Diabetes and Digestive and Kidney Diseases,
National Institutes of Health, Bethesda, MD; Institutional Review
Board, New England Research Institutes, Watertown, MA.
Laboratory
Serum HCV RNA and HCV genotype were determined as
described previously (Text S1) [17]. The methods used to extract
genomic DNA were described in an earlier publication [18].
Genotyping of IL28B SNPs was carried out by allele-specific real-
time PCR [19] at a high throughput facility. For each allele-
specific PCR reaction, 0.3 ng of DNA was amplified. Genotypes
were automatically called by an in-house software program
followed by manual curation without knowledge of phenotype.
Primer sequences can be found in the Text S1.
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HALT-C Trial. Analyses of virological response were
stratified by ethnicity and restricted to subjects who were
infected with HCV genotype 1. To examine the effect of IL28B
genotype over a range of possible virological responses, we divided
patients into four mutually exclusive outcome groups based on
serum HCV RNA levels during and after treatment: 1) null (,2
log10 IU/mL decrease at week 12); 2) partial early viral response
(EVR) only (week 12: .2 log10 decrease; week 20: detectable); 3)
relapse (week 20 and 48: undetectable; week 72: detectable) or
breakthrough (week 20 undetectable; detectable sometime
between week 20 and 48); 4) SVR (week 20, 48, and 72
undetectable). In these analyses, IL28B genotype frequencies were
determined for each virological response group. Using null
responders as the referent (i.e., baseline subject group) and
homozygosity for the ancestral allele (rs12979860-T or rs8099917-
T) as the baseline genotype, the genotype specific odds ratio (OR)
and 95% confidence interval (CI) were determined.
Among European American patients who were infected with
HCV genotype 1 (n=646), we used a step-wise algorithm
(selection criteria: entry, p=0.10; exit, p=0.05) to select variables
for a logistic regression model that was used to calculate adjusted
ORs and to estimate an individual’s probability of achieving SVR
or not. Candidate variables for this model were IL28B rs12979860
genotype and other factors that have been reported to be
associated with SVR. All variables listed in Table S2 were entered
into the step-wise model. Continuous variables were divided into
categories with a minimum of 50 subjects per category (Table S2)
and these variables were treated as ordinal predictors in the model,
if appropriate. No variables were forced into the model, but, for
the sake of comparison, we also created a model that was limited
to the clinical variable and another that was limited to IL28B
genotype. We used the likelihood ratio test to compare these
models for fit of the data. To examine whether rs12979860 and
rs8099917 were independently associated with virological re-
sponse, we constructed models including both variants and
compared them to single SNP models by the log likelihood test.
Among European American patients who were infected with
HCV genotype 1 (n=646), we used the leave-one-out cross-
validation (LOOCV) method [20] to estimate the probability of
SVR for each subject. A series of 646 logistic regression models
was created with each model excluding a different subject from the
dataset. An individual’s probability of achieving SVR was
obtained from the model to which they did not contribute,
making these estimates unbiased a priori predictions of the
probability of SVR.
We used the LOOCV predictions to estimate area under the
‘receiver operating characteristic’ curve (AUC), a popular measure
of model discrimination [21]. To test for differences in AUC
values between models, we computed a p-value based on a chi-
square test (1 df) that used a bootstrap variance estimate computed
by resampling the LOOCV predictions for subjects with SVR and
non-responders, and then repeating the AUC computations for
each bootstrap sample.
IDEAL Study. SVR rates according to the joint distribution
of HCV RNA level (#600,000, .600,000), METAVIR fibrosis
score (F0–2, F3–4) and IL28B rs12979860 genotype (CC, CT,
TT), have been published for 1,121 HCV-infected European
American patients who enrolled in the IDEAL Study (found in
Supplemental Table 4 of the paper by Thompson et al) [22]. The
combination of these three risk factors can be viewed as a single
predicator (X) with twelve (unordered) categories. We used Bayes’s
theorem to determine the distribution of X in IDEAL Study
subjects who achieved SVR and in those who did not. We then
randomly selected 10,000 values of X separately for IDEAL
subjects who achieved SVR and from non-responders, and
computed the logistic probability of SVR given X. We
calculated AUC as the probability that the score for a randomly
selected subject with SVR is greater than the score for a randomly
selected non-responder, where score is the probability of SVR for
a given X.
Results
Virological Response to Treatment in the HALT-C Trial
Demographic and clinical data at entry into HALT-C for all
lead-in subjects who had an IL28B genotype result are shown in
Table 1. Median age was 49 years, 72.4% were male, median pre-
treatment HCV RNA was 6.5 log10 IU/ml; 37.6% had cirrhosis.
Consistent with previous studies [5,9], there was evidence for
selection against the IL28B rs12979860-CC genotype among these
patients, who had failed both to clear HCV spontaneously and to
achieve SVR in response to prior therapy. IL28B rs12979860-CC
frequency was 25.7% among 732 European American subjects in
the Trial compared to 45.6% in the reference population
(p,.0001) and 10.8% in 148 African American Trial subjects
compared to 20.0% in the reference population (p=0.01).
Among European American patients who were infected with
HCV genotype 1 (n=646), the overall SVR rate was 14.2%. To
examine the relationship between IL28B genotype and a range of
virological responses, we performed an analysis among the 622
(96.3%) HCV genotype 1-infected European American patients
who could be fully classified for virological response. IL28B
rs12979860-CC frequency varied markedly by the degree of
virological response (Figure 1; Table S3): null responders
(referent), 6.9%; partial EVR, 24.4% (unadjusted OR,6.69;
,.0001); breakthrough/relapse, 48.2%; SVR, 48.9%. The
unadjusted OR observed for those with breakthrough/relapse
and SVR were approximately 20 (p ,.0001, each comparison),
but the frequency of rs12979860-CC did not differ between these
two groups even when other variables were considered in
multivariate models (p=0.56). Comparing subjects with undetect-
able HCV RNA at week 20 (breakthrough/relapse or SVR) to
those with detectable virus (null or partial EVR) yielded adjusted
ORs of 16.29 for rs12979860-CC (95% CI, 8.44–31.47; p,.0001)
and 2.02 for rs12979860-CT (95% CI, 1.16–3.52; p=0.01).
Among all European American subjects infected with HCV
genotype 1, we compared IL28B genotype between those who
achieved SVR and those who did not. Compared to rs12979860-
TT, the OR for rs12979860-CC was 5.29 (95% CI, 2.46–11.38;
p,.0001) and that for rs12979860-CT was 1.48 (95% CI, 0.69–
3.16; p=0.3). Fibrosis stage did not vary by rs12979860 genotype
(mean and median=4.0 for all three genotypes) in these subjects,
but, consistent with prior reports [5], higher median pre-treatment
HCV RNA levels were found in subjects with genotype
rs12979860-CC (6.74 log10 IU/mL; p,.0001) and rs12979860–
CT (6.50 log10 IU/mL; p=0.04) compared to rs12979860-TT
(6.41 log10 IU/mL). The logistic regression model included five
variables: IL28B genotype (three categories), pre-treatment HCV
RNA level (seven ordinal categories), AST/ALT ratio (five ordinal
categories), Ishak fibrosis score (five ordinal categories) and prior
treatment with ribavirin (yes/no). This model yielded an adjusted
OR of 7.56 (95% CI, 3.20–17.87; p,.0001) for rs12979860-CC
and an adjusted OR of 1.83 (95% CI, 0.82–4.11; p=0.14) for
rs12979860–CT.
The final model is described by this equation:
log odds=22.854020.35326fibrosis20.40676HCV RNA2
0.42686AST:ALT20.68446prior ribavirin+2.02266IL28B rs129
IL28B-Based Prediction Model for Hepatitis C
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ries for co-variates are: HCV RNA=6.50–6.74; AST:ALT=
0.50–0.74, fibrosis=3; prior ribavirin=yes; IL28B rs12979
860(TT). On the basis of these log odds ratio parameter
estimates, IL28B genotype was the strongest predictor of SVR
in this study.
Figure 1. Distribution of IL28B rs12979860 genotypes, by response to treatment with pegylated-interferon-a2a plus ribavirin
among European American subjects infected with HCV genotype 1, lead-in phase of the HALT-C Trial. EVR, early virological response;
BT, breakthrough; SVR, sustained virological response.
doi:10.1371/journal.pone.0020904.g001
Table 1. Demographic and clinical characteristics of subjects in the HALT-C Trial study of IL28B genotype.
All Lead-In Subjects (n=992) Prediction Model (n=646)
Characteristic
Age (median, IQR
a) 49 45–53 49 45–53
Race
White (n, %) 732 73.8 646 100.0
Black (n, %) 148 14.9 0
Hispanic (n, %) 85 8.6 0
Other (n, %) 27 2.7 0
Male (n, %) 718 72.4 487 75.4
Ishak Fibrosis Score
b
2 (n, %) 82 8.3 48 7.4
3–4 (n, %) 534 53.8 357 55.3
5–6 (n, %) 373 37.6 241 37.3
HCV Genotype 1 (n, %) 877 88.4 646 100.0
HCV RNA level (log 10) (median, IQR
a) 6.5 6.1–6.8 6.5 6.2–6.8
Prior treatment:
Interferon alone (n, %) 282 28.4 176 27.2
Interferon and ribavirin (n, %) 710 71.6 470 72.8
aIQR – Intra-quartile range (25th percentile–75th percentile).
bFinal assessment of fibrosis stage was performed by a panel of hepatopathologists.
doi:10.1371/journal.pone.0020904.t001
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genotype 1, 350 were maintained on at least 80% of full dose for
both pegylated-interferon-a2a and ribavirin for the first 20 weeks
of treatment. Among this ‘fully adherent’ subgroup, the association
between IL28B genotype and SVR (rs12979860-CC: adjusted
OR, 7.91; 95% CI, 2.80–22.35; p,.0001. rs12979860–CT:
adjusted OR, 1.75; 95% CI, 0.67–4.57; p=0.25) was similar to
that found among HCV genotype 1-infected European American
subjects as a whole.
Among 134 HCV genotype 1-infected African American
patients, eight achieved SVR. For rs12979860-CC, the unadjusted
OR was 12.69 (95% CI, 1.19–135.66; p=0.04) and adjustment for
covariates increased the association (adjusted OR, 48.02; 95% CI,
2.57–898.09; p=0.01). The rs12979860-CC genotype was much
more common in African American subjects with undetectable
HCV RNA at week 20 (n=21) than those with detectable virus
(adjusted OR, 15.88; 95% CI, 2.90–86.96; p=0.001). Hispanic
subjects who were infected with HCV genotype 1 were too few
(n=67) for a meaningful analysis of virological response.
IL28B rs8099917 has been associated with response to
treatment for chronic hepatitis C [5,6,7,8] and this SNP is in
strong linkage disequilibrium with rs12979860 [5]. Associations of
rs8099917 genotype with virological response were similar to those
for rs12979860, but models including both SNPs showed no
independent effect of rs8099917 (data not presented).
Prediction of Treatment Response in the HALT-C Trial
The subjects for the prediction model, European American
patients who were infected with HCV genotype 1, were similar to
HALT-C Trial lead-in subjects as a whole with regard to other
demographic and clinical variables (Table 1). The distribution of
IL28B rs12979860 genotypes among these 646 subjects was: CC,
24.0%; CT, 56.8%; TT, 19.2%.
The logistic regression model based on IL28B genotype plus
four clinical predictors of SVR (described above) fit the data better
than models that included the four clinical predictors only or
IL28B genotype only (p,0.001, both comparisons). For the full
model (IL28B genotype plus clinical predictors), AUC was 78.5%
compared to 73.0% for the model based on the clinical predictors
without IL28B genotype (p,0.001; Figure 2). AUC was 60.0% for
the model with IL28B genotype only.
Based on the LOOCV models, 30.2% of these HALT-C
subjects had an a priori predicted probability of achieving SVR
,5%, 56.7% had a predicted probability ,10%, 77.6% had a
predicted probability ,20% and 90.1% had a predicted
probability ,35% (Table 2). The distributions of a priori predicted
probabilities of SVR differed markedly between the 554 non-
responders and the 92 subjects who actually achieved SVR
(Figure 3). For example, 36.5% of non-responders had a predicted
probability $10%, compared to 84.8% of HALT-C subjects who
achieved SVR. As a result of this relationship, the IL28B genotype-
based model could predict which HALT-C subjects were more
likely to achieve SVR. Table 2 shows SVR rates under a range of
model-based treatment decision scenarios. For example, among
the 280 HALT-C subjects with a predicted probability $10%, the
observed SVR rate was 27.9%, compared to an SVR rate of 3.8%
among the 366 patients with a predicted probability ,10%. For
HALT-C subjects, a strategy of treating those with a predicted
Figure 2. Area under the ‘receiver operating characteristic’ curve (AUC) for models predicting the probability of sustained
virological response (SVR) - European American patients infected with HCV genotype 1, HALT-C Trial. Full model: IL28B rs12979860
genotype plus four clinical variables. AUC was calculated using predicted probabilities of SVR based on a series of leave-one-out cross-validation
logistic regression models.
doi:10.1371/journal.pone.0020904.g002
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subjects) would have yielded ,85% of the total number of patients
with SVR through treatment of 43% of the patients. Limiting
treatment to those with a predicted probability $15%, would
increase the SVR rate to 32.5% and decrease the number treated
to 194 (30.0% of total subjects), while also decreasing the number
who achieved SVR to 63 (68.5% of all subjects who actually
achieved SVR).
Figure 4 displays selected examples of SVR probabilities
predicted by the model, as well as the observed SVR rates overall
(14.2%) and by IL28B genotype (CC, 29.0%; CT, 10.3%; TT,
7.3%). Clinical profile 1consists of relatively favorable values for
the four clinical predictors (HCV RNA, 5.75–5.99; AST/ALT,
0.50–0.74; no prior ribavirin; fibrosis score, 3). Among individuals
with this clinical profile, the model predicted a probability of SVR
as 74.5% for patients with the IL28B-CC genotype, 41.5% for
Figure 3. Distributions of a priori predicted probability of sustained virological response (SVR) for 554 non-responders and 92
subjects who achieved SVR - European American patients infected with HCV genotype 1, HALT-C Trial. Predicted probabilities are
based on a series of leave-one-out cross-validation logistic regression models.
doi:10.1371/journal.pone.0020904.g003
Table 2. Number of subjects with various a priori predicted probabilities of SVR; projected SVR rates and numbers of patients
achieving SVR if decision to treat was based on predicted probablity of SVR estimated from LOOCV models among EA patents
infected with genotype 1, HALT-C Trial.
Predicted Probability SVR
Any 5% 10% 15% 20% 35%
Treatment
Decision Group # % # % # % # % # % # %
$Predicted Probability
SVR
Treat 646 100 451 69.8 280 43.3 194 30 145 22.4 64 9.9
,Predicted Probability
SVR
Defer 0 0 195 30.2 366 56.7 452 70 501 77.6 582 90.1
SVR Rate Treat 14.2 18.8 27.9 32.5 35.9 42.2
SVR Rate Defer N/A 3.6 3.8 6.4 8.0 11.2
SVR Achieved 92 100 85 92.4 78 84.8 63 68.5 52 56.5 27 29.3
SVR Not Achieved 0 0 7 7.6 14 15.2 29 31.5 40 43.5 65 70.7
doi:10.1371/journal.pone.0020904.t002
IL28B-Based Prediction Model for Hepatitis C
PLoS ONE | www.plosone.org 6 July 2011 | Volume 6 | Issue 7 | e20904IL28B-CT and 27.9% for IL28B-TT. Among individuals with the
‘intermediate’ clinical profile (Clinical profile 2: HCV RNA, 6.25–
6.49; AST/ALT, 0.75–0.99; no prior ribavirin, fibrosis score, 4),
the range in genotype-specific predicted probability of SVR was
30.0% (IL28B-CC, 37.3%; IL28B-CT, 12.6%; IL28B-TT, 7.3%).
With a very unfavorable non-genetic profile (Clinical profile 3:
HCV RNA, 6.75–6.99; AST/ALT, 1.00–1.24; prior ribavirin,
fibrosis score, 5), the model predicted a very low SVR probability
for all genotypes including IL28B-CC (5.7%).
Prediction of Treatment Response in the IDEAL Study
To determine whether both IL28B genotype and clinical
variables improve clinical prediction in a treatment naı ¨ve
population, we used published data [22] among 1,121 HCV
genotype 1-infected European American patients enrolled in the
IDEAL study. The overall SVR rate in this population was 45.3%.
AUC values were: IL28B genotype, HCV RNA and fibrosis,
73.7%; IL28B genotype, 67.8%; HCV RNA and fibrosis, 60.0%
(all AUC values differ from each other, p,.01).
Discussion
We demonstrated that IL28B genotype is a very strong predictor
of SVR among patients with advanced chronic hepatitis C who
failed previous therapy and then used these data to create a model
to predict the probability of SVR based on IL28B genotype and
selected clinical factors. The model must be validated in other
populations before it can be implemented clinically, but our results
provide ‘proof of concept’ that this approach has the potential to
improve the care of patients with chronic hepatitis C. Patients with
advanced chronic hepatitis C who have failed to respond to prior
treatment for chronic hepatitis C have a very low rate of SVR
overall, nonetheless the model identified patient profiles associated
with a high probability of treatment response. As expected, most
HALT-C subjects had a profile associated with a very low a priori
probability of achieving SVR. Treatment decisions involve many
considerations, but our work suggests that identifying patients with
a low likelihood of success and advising them to await availability
of more effective regimens could reduce the number of patients
who would be exposed to a treatment with substantial adverse
effects from which they will not derive a benefit, while having
much less impact on the number who respond. For example, if
treatment of HALT-C subjects had been limited to patients with a
predicted probability $10%, 57% would have been spared
treatment, the SVR rate would have been double and the number
of subjects achieving SVR would have been 85% of that attained
through treating the entire group.
Although IL28B genotype was the strongest predictor of SVR in
this study, the prediction model was greatly improved by the
inclusion of four parameters commonly available in clinical
practice (pre-treatment HCV RNA level; AST/ALT ratio; fibrosis
score; whether or not the patient received ribavirin during
previous interferon-based treatment). In building the model, we
divided continuous variables into multiple categories to avoid
assumptions about the relationship between a variable and SVR
based solely on the associations observed among HALT-C
subjects. In addition, although the difference in SVR rate between
rs12979860-CT and rs12979860-TT (adjusted OR, 1.83) did not
reach statistical significance (p=0.14), we retained all three IL28B
genotype categories, which is consistent with the approach of some
other groups [7]. The number of variables and categories in the
model should not present a barrier to its clinical implementation,
as these could be accommodated easily in a computer-based
instrument.
Some variables previously associated with SVR were not
selected into our logistic regression model. The effect of these
variables may have been accounted for by variables in the model
or our statistical power may have been inadequate to select these
variables. Additional subjects might allow us to add variables to
the model and improve its predictive ability.
Published data on joint SVR rates by IL28B genotype, HCV
RNA level and fibrosis score (from the IDEAL study), allowed us
Figure 4. Observed and predicted probabilities of sustained virological response (SVR), by IL28B rs12979860 genotype, among
European American patients infected with HCV genotype 1, HALT-C Trial. ‘Overall’ probabilities were directly observed. Probabilities for the
selected clinical profiles were predicted from the model.
doi:10.1371/journal.pone.0020904.g004
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when both IL28B genotype and clinical variables are considered.
However, individual patient data are required for our model and
with additional data, our modeling approach could be extended.
The HALT-C Trial was limited to subjects with advanced chronic
hepatitis C who had failed to respond to previous interferon-based
treatment. In developing the model, we further restricted subjects
to those who were infected with HCV genotype 1 and of European
ancestry because there were too few subjects in other ‘race’ or viral
genotype groups for meaningful analysis. Given sufficient data, a
prediction model for chronic hepatitis C treatment response could
encompass the full range of HCV-infected patients, including
those previously naı ¨ve for peg-interferon- alfa/ribavirin and those
receiving regimens that include additional agents. Our modeling
approach also could be expanded to include data on rapid
virological response, but, unfortunately, those data are incomplete
among HALT-C subjects. A ‘non-invasive’ prediction model that
would not require measurement of fibrosis by liver biopsy might be
desirable, but development and evaluation of such a model
requires subjects encompassing the full range of fibrosis values.
Direct acting anti-viral agents that inhibit HCV replication,
currently in late clinical development, promise to improve the
SVR rate for patients who have failed to respond to treatment with
interferon- alfa and ribavirin [23], as well as for patients who have
not been treated for chronic hepatitis C previously [24,25]. These
compounds, which select drug-resistant HCV strains if used alone
[26], will likely be combined with peginterferon alfa/ribavirin to
reduce viral replication and mutational escape. Among patients
who were treated with a regimen of peginterferon alfa/ribavirin
plus the HCV-protease inhibitor telaprevir, 84% of those with the
IL28B rs12979860-CC genotype achieved SVR compared to 32%
among those with either IL28B rs12979860-CT or –TT [27].
Indirect evidence also suggests that IL28B genotype may be
associated with response to a peginterferon alfa/ribavirin/
telaprevir regimen. A recent trial among HCV-infected patients
who had failed initial peginterferon alfa/ribavirin treatment found
that retreatment with a regimen that included telaprevir was more
effective among patients who had relapsed during previous
treatment compared to previous nonresponders [23]. Given the
strong association we observed between IL28B genotype and
breakthrough/relapse, it is quite plausible that IL28B genotype is
associated with response to a peginterferon alfa/ribavirin/
telaprevir regimen. Therefore, an IL28B genotype-based model
may identify patients who are at high risk for treatment failure
(and selection of resistant HCV strains) when treated with this
regimen.
Our work demonstrates that a model based on IL28B genotype
and a few clinical variables can provide individualized predictions
for the probability of achieving SVR after treatment with peg-
interferon- alfa/ribavirin. If the IL28B genotype-based model is
validated in a wide range of patients with chronic HCV infection,
then development of a computer based algorithm for clinical
decision making would seem warranted. Such a tool could
improve patient outcomes among patients treated for chronic
hepatitis C by increasing SVR rates and reducing the frequency of
futile treatment, with its substantial costs and adverse effects.
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